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ABSTRACT: Virus-like particles are very interesting tools for
application in bionanotechnology, due to their monodisperse
features and biocompatibility. In particular, the cowpea
chlorotic mottle virus (CCMV) capsid has been studied
extensively as it can be assembled and disassembled reversibly,
facilitating cargo encapsulation. CCMV is, however, only stable
at physiological conditions when its endogenous nucleic acid
cargo is present. To gain more ﬂexibility in the type of cargo
encapsulated and to broaden the window of operation, it is
interesting to improve the stability of the empty virus-like
particles. Here, a method is described to utilize the CCMV
capsid at close to physiological conditions as a stable, enzyme-
ﬁlled nanoreactor. As a proof-of-principle, the encapsulation of T4 lysozyme (T4L) was chosen; this enzyme is a promising
antibiotic, but its clinical application is hampered by, for example, its cationic character. It was shown that four T4L molecules
can successfully be encapsulated inside CCMV capsids, while remaining catalytically active, which could thus improve the
enzyme’s application potential.
■ INTRODUCTION
Virus-like particles (VLPs) are protein-based nanocages
composed of a discrete number of viral capsid proteins.1 In
contrast to some other types of nanoparticles, such as
liposomes or polymeric vesicles, VLPs are very monodisperse
in shape and size. Of special interest is the cowpea chlorotic
mottle virus (CCMV), an icosahedral plant virus, which
normally adopts T = 3 symmetry. This capsid consists of 180
identical 20 kDa capsid proteins and has an inner and outer
diameter of 18 and 28 nm, respectively.2,3 The CCMV VLP is
able to undergo reversible, pH-dependent assembly and
disassembly, even in the absence of its viral RNA.4 At pH
7.5, the capsid disassembles into 90 protein dimers, and by
lowering the pH to 5.0, the original structure is reformed. This
property has been used to encapsulate inorganic materials,5,6
negatively charged polymers,7,8 and enzymes9 by adding these
molecules to the media during the assembly process of the
protein dimers.
The endogenous assembly behavior of CCMV VLPs does
not allow for their facile application in biological settings, as the
capsids will disassemble at a physiologically neutral pH.
Therefore, a modiﬁed protein-based block copolymer of the
CCMV capsid protein, containing an N-terminal elastin-like
polypeptide (ELP) block, was previously developed in our
lab.10 ELPs are stimulus-responsive polymers, derived from
elastin, which can switch from a water-soluble state to a
collapsed, insoluble state, upon a change in the environmental
conditions, such as temperature, pH, (bivalent) cations, and salt
concentration of the solution.11,12 ELPs consist of repeats of
the VPGXG pentapeptide, where X is any natural amino acid
except proline. Previously, the stimulus-responsive polypeptide
block was placed at the N-terminal end of the CCMV capsid
protein, replacing the cationic RNA-binding domain. The
introduction of the ELP resulted in a new assembly pathway:
ELP-induced assembly resulted in the formation of T = 1
capsids, consisting of 30 protein dimers, after an increase of the
salt concentration at pH 7.5. Capsids with a T = 3 symmetry
could still be formed via the endogenous pH-induced assembly
pathway.
Even though the newly developed ELP-CCMV capsid
proteins could assemble at physiological pH, still a high salt
concentration (∼2 M NaCl) was needed to form the capsids.
Therefore, a third assembly mechanism for the ELP-CCMV
capsid proteins was introduced, making use of the metal-
binding properties of the hexahistidine tags at the N-terminus
of ELP-CCMV, which had initially been introduced to facilitate
protein puriﬁcation through aﬃnity chromatography.13 The
addition of divalent ions to ELP-CCMV, such as nickel or
cobalt, resulted in local clustering of the capsid proteins,
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lowering the transition temperature of the ELP blocks and
subsequently leading to capsid assembly at pH 7.5, without the
need for a high salt concentration. This has set the stage to use
CCMV capsids as enzyme nanoreactors at non-native and
physiological conditions.
Lysozyme was chosen as the model enzyme to be
encapsulated in the nanoreactor. This enzyme plays a key
role in the human immune system, as it protects our body from
Gram-positive pathogens, such as Bacillus and Streptococcus. It
does so by cleaving the core β-(1,4) glycosidic bond between
N-acetylmuramic acid and the fourth carbon atom of the N-
acetylglucosamine of bacterial cell wall peptidoglycans, resulting
in bacterial lysis and death.14 Human lysozyme has been
successfully applied in early studies to treat experimentally
induced pneumonia using hamster models, which has laid the
foundation for clinical testing of lysozyme for antibiotic
treatments.15,16 The enzyme has some disadvantageous proper-
ties, however, which hamper its application in a clinical setting.
For instance, the cationic character of lysozyme can lead to
aggregation with negatively charged biopolymers, resulting in
inhibition of its antibacterial properties. Additionally, lysozyme-
speciﬁc inhibitors exist, which also limits the clinical eﬃcacy of
lysozyme. So far, only genetic engineering has been used to
address these problems.17−20 In some cases, the engineered
variants did indeed show improved properties. Changing the
lysozyme genetic sequence, however, has also led to the
introduction of new unexpected and unfavorable properties.
We set out to encapsulate lysozyme in a nanocage structure,
in order to protect it against harmful external conditions or
molecules, allowing the enzyme to remain active without the
need for extensive genetic engineering of the T4L sequence.
Since the lysozyme activity drops signiﬁcantly upon an increase
in ionic strength, a nanoreactor is required which is stable
under physiological conditions.21,22 We hypothesized that the
metal ion-stabilized ELP-CCMV particles might be very
suitable nanocarriers for this purpose.
In order to encapsulate lysozyme, statistical encapsulation
during assembly of the ELP-CCMV capsids would probably not
yield a high enough encapsulation eﬃciency due to the cationic
character of lysozyme. Therefore, we chose to use a covalent
coupling strategy, which has previously been published by our
group.23,24 Brieﬂy, we used Sortase A (SrtA) to modify the N-
terminus of ELP-CCMV with diﬀerent cargoes, which
eventually end up at the interior of the VLPs (Figure 1).
SrtA is present in Gram-positive bacteria, where it anchors
surface proteins to the bacterial cell wall. It recognizes proteins
with the sorting signal LPXTG (where X = any amino acid).
SrtA cleaves the bond between threonine and glycine, after
which an N-terminal glycine residue attacks the intermediate.
We aimed to introduce the sorting signal LPETG onto the
C-terminus of T4 lysozyme (T4L), using a single step of
genetic engineering, in order to couple it to the N-terminus of
ELP-CCMV using SrtA (Figure 1). After optimization of the
coupling reaction and subsequent assembly and metal ion-
mediated stabilization of the capsids, we investigated the
activity of lysozyme after coupling to ELP-CCMV by
monitoring the degradation of the cell walls of Micrococcus
luteus (M. luteus), a Gram-positive bacterium.
■ EXPERIMENTAL SECTION
Materials. Hot start II HF DNA polymerase, dNTPs, restriction
enzymes, and T4 DNA ligase were obtained from New England
Biolabs. The DNA oligos were synthesized by Biolegio. Ampicillin was
purchased from MP Biomedicals. Chloramphenicol was obtained from
Sigma-Aldrich. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was
purchased from Acros. Ni-NTA agarose beads were obtained from
Qiagen. The ﬂuorescein conjugated Micrococcus luteus was purchased
as part of the EnzChek Lysozyme Assay Kit from Fisher Scientiﬁc.
UV−Vis Absorbance Measurements. Protein concentrations
were measured on a Varian Cary 50 Conc UV−vis spectrometer using
a quartz cuvette with a path length of 3 mm. Protein concentrations
were calculated using the theoretical extinction coeﬃcients.25 Samples
were centrifuged prior to the measurements.
Mass Spectrometry. Protein mass characterization was performed
by electrospray ionization time-of-ﬂight (ESI-TOF) on a JEOL
AccuTOF CS. Deconvoluted mass spectra were obtained using
MagTran 1.03 b2. Isotopically averaged molecular weights were
calculated using the “Protein Calculator v3.4” at http://protcalc.
sourceforge.net. Protein samples were desalted by spin ﬁltration with
MQ (ﬁnal concentrations approximately 20 μM).
Size Exclusion Chromatography (SEC). SEC measurements
were performed on a Superose 6 increase 10/300 column (GE
Healthcare). Analytical and preparative SEC measurements were
executed on a Shimadzu LC-2010AHT HPLC and Agilent 1260
bioinert HPLC, respectively. Samples were separated on the column
with a ﬂow rate of 0.5 mL/min.
Transmission Electron Microscopy (TEM). TEM grids (FCF-
200-Cu, EMS) were glow-discharged using a Cressington carbon
coater and power unit. Protein samples (0.2 mg/mL, 5 μL) were
applied on the glow-discharged grids and incubated for 1 min. The
samples were carefully removed using a ﬁlter paper and the grid was
Figure 1. Schematic representation of the Sortase A-mediated N-terminal functionalization of hexahistidine-tagged ELP-CCMV capsid protein
dimers with LPETG-modiﬁed T4 lysozyme and subsequent enzyme encapsulation via capsid formation. Capsid stabilization with Ni2+ ions results in
capsids which are stable at low NaCl concentrations and allows the degradation of the cell wall of M. luteus by lysozyme. Adapted in part with
permission from ref 13. Copyright 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
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allowed to dry for at least 15 min. Then the grid was negatively stained
by applying 2% uranyl acetate in water (5 μL). The staining solution
was removed after 15 s and the grid was allowed to dry for at least 15
min. The samples were analyzed on a JEOL JEM-1010 TEM.
Microplate Reader Experiments. Microplate reader experiments
were performed on a Tecan Spark 10 M microplate reader at 21 °C.
Samples were centrifuged prior to analysis. Buﬀers were ﬁltered prior
to use. Excitation and emission wavelengths were set to 485 and 530
nm, respectively. All measurements were done in triplicate.
Dynamic Light Scattering (DLS) Measurements. DLS
measurements were performed on a Malvern Zetasizer Nano ZSP at
20 °C. Samples were centrifuged prior to analysis. Buﬀers were ﬁltered
prior to use. All measurements were done in triplicate, and the average
of the triplicate measurements was plotted.
SrtA-Mediated Coupling Experiments. For a typical SrtA-
mediated coupling experiment, stock solutions of SrtA, G-ELP-
CCMV, and T4L-LPETG were prepared in Sortase buﬀer. If a
component had been dissolved in another buﬀer, it was spin ﬁltrated
to Sortase buﬀer (10 kDa MWCO, 3 × 10 min). The components
were added together to ﬁnal concentrations of 0−100 μM SrtA, 50 μM
G-ELP-CCMV, and 50 μM T4L-LPETG. The solutions were shaken
at 21 °C for 24 h. The reaction progress was followed by SDS-PAGE
analysis.
SrtA-Mediated Coupling Experiments, Followed by Capsid
Puriﬁcation. For a typical SrtA-mediated coupling experiment, stock
solutions of SrtA, G-ELP-CCMV, and T4L-LPETG were prepared in
Sortase buﬀer. If a component had been dissolved in another buﬀer, it
was spin ﬁltrated to Sortase buﬀer (10 kDa MWCO, 3 × 10 min). The
components were added together to ﬁnal concentrations of 0/10 μM
SrtA, 50 μM G-ELP-CCMV, and 0/50 μM T4L-LPETG. The
solutions were shaken at 21 °C for 3 h. The capsids were assembled
to either pH 5.0 capsid buﬀer by spin ﬁltration (10 kDa MWCO, 3 ×
10 min) or pH 7.5 capsid buﬀer by dialysis (Spectra/Por 2 dialysis
tubing, 12−14 kDa MWCO, 25 mm ﬂat width, 3 × 20 min).
Subsequently, the capsids were isolated using preparative SEC. The
combined capsid fractions were concentrated by spin ﬁltration,
analyzed, and used for further experiments.
Activity Assay with Free T4L. Lysozyme activity of free T4L and
T4L-LPETG was measured by observing the degradation of
ﬂuorescently labeled M. luteus cell walls (EnzChek lysozyme assay).
An increase in ﬂuorescence indicated the presence of active lysozyme,
as the degradation of the cell walls reduced the quenching of the
ﬂuorescent groups. The ﬂuorescently labeled substrate was diluted
from 1 mg/mL in MQ to 50 μM in the desired buﬀer. The substrate
(50 μL) was added to T4L or T4L-LPETG (50 μL, 2 μM in the
desired buﬀer) in triplicate in a 96-well plate. The ﬂuorescence
intensity was then followed for 60 min at 21 °C with intermediate
shaking steps on a Tecan Spark 10 M microplate reader (excitation
wavelength 485 nm, emission wavelength 530 nm). The initial slopes
of the curves were taken as a measure of the hydrolytic activity.
Activity Assay with Encapsulated T4L (and Related
Controls). The isolated and concentrated capsid fractions (see SrtA-
Mediated Coupling Experiments, Followed by Capsid Puriﬁcation)
were diluted to a concentration of approximately 200 μM by
measuring the OD280 of the concentrated capsid solution and diluting
to an OD280 of 1.4. Subsequently, NiCl2 (900 μM in either pH 5.0
capsid buﬀer or pH 7.5 capsid buﬀer) or buﬀer (equal volume as the
capsid solution) was added (ﬁnal protein concentration is approx-
imately 100 μM). The mixtures were incubated for 30 min at room
temperature. Subsequently, the mixtures were dialyzed to reaction
buﬀer (Spectra/Por 4 dialysis tubing, 12−14 kDa MWCO, 10 mm ﬂat
width, 3 × 20 min; solutions with Ni2+ separately from solutions
without Ni2+ ions, to prevent potential capsid formation in the control
samples during dialysis). The activity assay with the capsids was then
executed as described in the section Activity Assay with Free T4L,
using 50 μL of the capsid solution of approximately 100 μM per
reaction.
■ RESULTS AND DISCUSSION
The ELP-CCMV construct was designed such, that it displayed
a glycine residue on its N-terminus for the SrtA reaction (G-
ELP-CCMV). A T4L construct was modiﬁed to display the
Sortase recognition motif LPETG at its C-terminus (T4L-
LPETG). A hexahistidine tag was additionally included at the
C-terminus of T4L-LPETG, for facile puriﬁcation via aﬃnity
chromatography. As a control, a T4L construct was prepared
with a C-terminal hexahistidine tag, but lacking the LPETG
recognition motif. The proteins were subsequently expressed in
Escherichia coli (E. coli), followed by puriﬁcation through Ni2+
aﬃnity chromatography (see Supporting Information for
experimental procedures and characterization of the expressed
proteins).
Next, the Sortase-mediated coupling of T4L-LPETG to G-
ELP-CCMV was evaluated. To this end, diﬀerent equivalents of
SrtA were added to a mixture of T4L-LPETG and G-ELP-
CCMV. The coupling reaction was followed over time by
polyacrylamide gel electrophoresis (SDS-PAGE; Figure 2A).
Formation of both the intermediate T4L-SrtA and the desired
product T4L-ELP-CCMV could be observed over time. As
Figure 2. Analysis of the SrtA-mediated coupling of T4L-LPETG to
G-ELP-CCMV. (A) SDS-PAGE analysis of the conjugation over time,
with diﬀerent equivalents of SrtA. Protein bands were visualized by
Coomassie blue staining. (B) Conversions of G-ELP-CCMV to T4L-
LPETG-ELP-CCMV after 7 and 24 h, based on quantitative ImageJ
analysis of the SDS-PAGE results shown in (A). (C) Deconvoluted
ESI-TOF mass spectrum of a reaction mixture with 1.0 equiv SrtA
after 24 h. (D) Deconvoluted ESI-TOF mass spectrum of a reaction
mixture with 0 equiv SrtA after 24 h. The expected molecular weights
are 21947.5 Da (SrtA, blue), 22253.4 Da (G-ELP-CCMV, pink),
19904.6/20035.8 Da (T4L-LPETG/M-T4L-LPETG, yellow), and
41203.1/41334.3 Da (T4L-ELP-CCMV/M-T4L-ELP-CCMV, green).
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expected, the addition of higher equivalents of SrtA, compared
to the reactants, resulted in a faster reaction and more product
formation after 24 h, as indicated by quantitative ImageJ
analysis of the SDS-PAGE results (Figure 2B). Product
formation was further conﬁrmed by electrospray ionization
time-of-ﬂight (ESI-TOF) mass spectrometry analysis of the
reaction mixtures after 24 h (Figure 2C). No product formation
was observed using SDS-PAGE and ESI-TOF analysis when no
SrtA was added to the reaction mixture (Figures S1 and 2D).
A conventional way to monitor lysozyme activity is to follow
degradation of lyophilized M. luteus cells. In this assay, a
decrease in turbidity of the cell wall suspension indicates the
presence of active lysozyme. Even though this assay has been
the benchmark in lysozyme activity assays for a long time, the
sensitivity and reproducibility of this assay are not optimal. In
another procedure, the M. luteus cell walls are ﬂuorescently
labeled to such a degree, that the ﬂuorescence becomes
quenched. If now lysozyme-catalyzed degradation of the cell
walls takes place, a dramatic increase of ﬂuorescence occurs,
making this assay much more sensitive. We chose to use the
ﬂuorescence-based assay for the next series of experiments.
First, the activity of hexahistidine-tagged T4L and the
LPETG-modiﬁed variant were tested in the benchmark
phosphate buﬀer pH 7.5, supplied with the substrate kit
(Figure S2). Signiﬁcant activity was observed for both enzymes
under the experimental conditions used. A slight decrease in
activity was observed as a consequence of the introduction of
the LPETG sequence in T4L-LPETG. Next, we tested whether
T4L would become inactive under conditions at which the G-
ELP-CCMV capsid proteins are assembled, that is, pH 5.0
capsid buﬀer or pH 7.5 capsid buﬀer with 2.0 M NaCl. In
neither buﬀer, activity was observed. Also, in pH 7.5 dimer
buﬀer, containing 500 mM NaCl, no activity could be observed.
Reducing the NaCl concentration of the pH 7.5 dimer buﬀer to
150 mM did result in lysozyme activity. Additionally, lowering
the Tris·HCl concentration from 50 to 10 mM further
increased the activity. At pH 5, no activity was observed at
all, even upon lowering the ionic strength of the buﬀer. These
results conﬁrm that, in order to ensure activity of the
encapsulated T4L, further stabilization of the G-ELP-CCMV
capsids with metal ions is required as no lysozyme activity was
observed in buﬀers in which the capsids remain assembled
without additional stabilization.
Subsequently, a protocol was developed for capsid assembly
and stabilization from a SrtA reaction mixture, containing
modiﬁed and nonmodiﬁed G-ELP-CCMV capsid protein
dimers, SrtA and free T4L-LPETG. This was done based on
previous work on both the SrtA-mediated modiﬁcation of the
N-terminus of CCMV capsid proteins and Ni2+-induced capsid
formation of ELP-CCMV.13,23,24 In the ﬁrst attempt, Ni2+ ions
were directly added to the reaction mixture to induce the
formation of stabilized capsids, followed by preparative size
exclusion chromatography (SEC) puriﬁcation of the assembled
capsids. This, however, did not lead to the formation of
monodisperse capsids, as indicated by SEC analysis (Figure
S3). Instead, tailing of the capsid peak was observed and a very
low amount of capsids was obtained. A possible explanation
could be that the Ni2+ ions also interact with other proteins in
the solution with a hexahistidine tag, such as SrtA and free T4L-
LPETG. Therefore, it was decided to ﬁrst induce capsid
formation from the SrtA reaction mixture via either pH-induced
assembly or salt-induced assembly, followed by preparative SEC
puriﬁcation and subsequent stabilization of the capsids with
Ni2+ ions. Both assembly methods, that is, lowering the pH of
the reaction mixture from 7.5 to 5.0 or increasing the NaCl
concentration of the reaction mixture from 150 to 2000 mM,
were tested, and both resulted in the formation of capsids from
the reaction mixtures (Figure 3A). After successful puriﬁcation
of both the T = 3 and T = 1 capsids, it was tested whether these
capsids could be stabilized by Ni2+ ions. To this end, the capsids
were incubated with Ni2+ ions and subsequently dialyzed to the
T4L-compatible pH 7.5 dimer buﬀer with reduced NaCl and
Tris·HCl concentrations (will be referred to as reaction buﬀer).
DLS analysis showed that the T = 3 capsids fell apart during
dialysis, indicating that the stabilizing eﬀect of the metal ions is
not enough in this case (Figure 3B). The T = 1 particles,
however, could be stabilized by Ni2+: capsids were still present
after dialysis to the reaction buﬀer (Figure 3C). Transmission
electron microscopy (TEM) analysis of the particles directly
Figure 3. (A) Size exclusion chromatograms of SrtA reaction mixtures
after dialysis to either pH 5.0 capsid buﬀer (pH-induced, pink line) or
pH 7.5 capsid buﬀer containing 2.0 M NaCl (salt-induced, orange
line). Capsids are observed around an elution volume of 10−13 mL,
with the T = 3 particles eluting earlier due to their larger size. (B) DLS
measurements of the T = 3 capsid fraction shown in (A) after
preparative SEC puriﬁcation, after subsequent incubation with Ni2+
ions, and after subsequent dialysis to reaction buﬀer. (C) DLS
measurements of the T = 1 capsid fraction shown in (A), after
incubation with (solid line) or without (dashed line) Ni2+ ions,
followed by dialysis to reaction buﬀer. Capsids are expected around
20−30 nm, and dimers are expected below 10 nm.
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after preparative SEC in pH 7.5 capsid buﬀer, and after
stabilization and dialysis to reaction buﬀer showed equally sized
particles of approximately 19.6 nm (Figure S4). When the Ni2+
ions were left out, disassembly toward the capsid protein
dimers occurred during dialysis, as expected. We therefore
continued with the stabilized T = 1 particles for the remaining
experiments.
After having developed a successful protocol for the
formation and stabilization of G-ELP-CCMV T = 1 capsids
after the coupling reaction with T4L-LPETG, the lysozyme
encapsulation eﬃciency was determined. To this end, the
composition of the isolated capsid fraction was analyzed by
SDS-PAGE (Figure 4A). As a control, capsids were prepared
from reaction mixtures lacking either SrtA or T4L-LPETG. A
band corresponding to G-ELP-CCMV was observed for all
three capsid samples. As expected, the coupled product T4L-
ELP-CCMV was only observed when both SrtA and T4L-
LPETG had been present during the coupling reaction. ImageJ
analysis of this gel suggested that each T = 1 capsid contained
approximately 4 T4L enzymes. This is quite a remarkable
amount of enzymes to ﬁt in such a small compartment, taking
into account that lysozyme has a cationic surface charge.
To investigate the enzymatic activity of T4L after
encapsulation in the capsids, the capsids in the reaction buﬀer
were exposed to M. luteus cell walls, labeled with ﬂuorophores
of which the ﬂuorescence was self-quenched (Figure 5). Also
dimers, obtained from the procedure where the Ni2+ ions had
been left out before dialysis to reaction buﬀer, were added to
the M. luteus substrate. As a control, samples were prepared
from SrtA reaction mixtures deﬁcient of either SrtA or T4L-
LPETG. The T4L-LPETG concentration in the active capsid
and dimer samples was determined based on the ratio of T4L-
ELP-CCMV and G-ELP-CCMV, determined by SDS-PAGE
analysis (Figure 4A) and comparison to a calibration curve of
G-ELP-CCMV (Figure 4B). Only when both SrtA and T4L-
LPETG had been present during the reaction, a ﬂuorescence
increase was observed. This showed that the cargo was available
to react with the substrate after encapsulation, as shown
previously when CalB was encapsulated using a similar
strategy.24 Free T4L-LPETG, in the same concentration as
present in the active capsid and dimer samples, was more active
(i.e., approximately seven times) than T4L-LPETG attached to
G-ELP-CCMV (Figure 5). Additionally, free T4L-LPETG,
subjected to the same protocol, but without SrtA and G-ELP-
CCMV present, was equally active as T4L-LPETG that had not
been subjected to this protocol (Figure S5). Hence, attachment
of ELP-CCMV did aﬀect lysozyme activity to some extent.
Attempts to disassemble the metal ion-stabilized capsids into
capsids by the addition of an excess of chelating agent
ethylenediaminetetraacetic acid (EDTA) failed. Probably, the
crowded interior of the loaded capsids did not allow EDTA to
reach the metal ions near the hexahistidine tags.
Surprisingly, the activities of the T4L-modiﬁed dimers and
capsids were very similar (Figure 5). Even if the M. luteus cells
had been fragmented during lyophilization, resulting in cell wall
fragments which could more easily come into contact with
enzyme molecules, we would still expect to see a diﬀerence in
activity, that is, some eﬀect of diﬀusion through the pores of the
T = 1 capsids. To be sure that the addition of the substrate did
not result in capsid disassembly, DLS measurements were
performed on the capsids before and after substrate addition
(Figure S6). No signs of capsid disassembly were observed,
suggesting that the capsids remained intact during the activity
assay. We could also rule out aspeciﬁc adhesion of free T4L-
LPETG to the outside of the capsids, as no free T4L-LPETG
was observed on the SDS-PAGE gels after capsid puriﬁcation
(Figure 4A). Lastly, the eﬀect of G-ELP-CCMV itself on T4L
Figure 4. SDS-PAGE analysis of isolated capsid fractions after the
SrtA-mediated coupling of T4L-LPETG to G-ELP-CCMV. (A) Left:
comparison between capsids prepared from reaction mixtures
containing both SrtA and T4L-LPETG (++), no SrtA (−SrtA), and
no T4L-LPETG (−T4L). Right: calibration curve of G-ELP-CCMV.
Protein bands were visualized by Coomassie blue staining. (B)
Calibration curve of the peak area observed on SDS-PAGE, related to
the amount of G-ELP-CCMV in μg. The calibration curve was
constructed based on the SDS-PAGE results shown in (A).
Figure 5. Catalytic activity of capsids where both SrtA and T4L-
LPETG had been present during the SrtA reaction (++) or where
either SrtA or T4L-LPETG had been left out (−SrtA and −T4L-
LPETG, respectively). The activity was measured using the EnzChek
lysozyme assay. +Ni2+: nickel ions were added before dialysis to
reaction buﬀer, to stabilize the capsids; −Ni2+: nickel ions were not
added before dialysis to reaction buﬀer, yielding dimers. The activity of
the ++ samples was compared to the activity of nonencapsulated T4L-
LPETG, in approximately the same concentration as the capsid
samples. As a control, the background reaction in reaction buﬀer was
measured.
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activity was investigated by incubating free T4L-LPETG with
free G-ELP-CCMV, followed by a measurement of the
lysozyme activity (Figure S7). No eﬀect of the presence of
G-ELP-CCMV was observed on the T4L activity. This excludes
any eﬀects arising from aspeciﬁc ionic interactions between
lysozyme and the CCMV capsid protein. From the experiments
above, we can conclude that the T4L enzyme molecules retain
their activity after encapsulation inside the CCMV capsids and
that their activity is somewhat reduced compared to free T4L.
■ CONCLUSION
We have utilized a protein-based block copolymer of CCMV
and its expanded assembly proﬁle to create nanoreactors which
can function under conditions with similar salt concentrations
as present in the physiological environment. As a proof-of-
principle, T4 lysozyme was successfully encapsulated via
selective attachment to the interior of the CCMV capsids.
The activity of this enzyme is highly dependent on the salt
concentration and pH of the environment. Only after addition
of metal ions to the CCMV capsids, these could remain stable
at conditions at which its cargo was also active. A high
encapsulation eﬃciency of approximately 4 enzymes per T = 1
capsid was achieved, indicating that the unfavorable interaction
between the cationic lysozyme molecules was overcome.
Possibly these charges were neutralized by interactions with
the interior of the capsids. It was shown that on incorporation
in the CCMV capsids, the enzyme molecules were available to
interact with the substrate and remained active. This opens
perspectives to use the shielded T4L in antibiotic applications.
Attempts to disassemble the capsids by the addition of EDTA,
which should bind the metal ions, have not been successful so
far. Future research could focus on methods to disassemble
these capsids, and expansion of the assembly/disassembly cycle
toward a switchable nanoreactor. Furthermore, we believe this
strategy is widely applicable to diﬀerent types of cargo, and
provides interesting opportunities for the in vitro and possible
in vivo application of the CCMV capsids.
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